The recently US Food and DrugAdministration-approved adeno-associated virus (AAV) serotype 9 (AAV9) carrying SMNcomplementary DNA encoding the missing SMN protein, AVXS-101 (Zolgensma®), is asingle-dose gene-replacement therapy for SMA. Here, SMN1 is linked to proximal spinal muscular atrophy.